AA
AEGR

ALPS Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

ALPS Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-14,103
Closed -$369K – 694
2015
Q1 		$369K Buy
+14,103
New +$359K ﹤0.01% 619

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ALPS Advisors's AEGR Position: Q2 2015 in Review

ALPS Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2015, closing a stake of 14,103 shares — an estimated $369K sold.

ALPS Advisors first reported a position in AEGR in Q1 2015 and held it in 1 quarter. The position peaked at $369K in Q1 2015. 97 funds tracked by Wall St. Rank hold AEGR as of Q2 2015.

  • ALPS Advisors reported no remaining Aegerion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • ALPS Advisors sold 14,103 Aegerion Pharmaceuticals shares in Q2 2015, an estimated $369K.
  • ALPS Advisors first reported a position in Aegerion Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • ALPS Advisors's Aegerion Pharmaceuticals position peaked at $369K in Q1 2015.
  • 97 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2015.

Based on ALPS Advisors's 13F filing for Q2 2015, filed 12 Aug 2015.